Why the study?
Do CYP3A4*22, PPAR-α, and ARNT polymorphisms alter clopidogrel response (platelet aggregation) in patients with coronary artery disease?
Population
211 subjects of mixed racial background with established coronary artery disease who had received clopidogrel
Comparison
Presence of CYP3A4*22, PPAR-α, and ARNT variant… vs Different genotypes (wild-type or other variants)
Design
Cohort
Authors
Loading...
CYP3A4*22, PPAR-α, and ARNT variants do not alter clopidogrel response; hypothesis-generating and should not change practice.
Do CYP3A4*22, PPAR-α, and ARNT polymorphisms alter clopidogrel response (platelet aggregation) in patients with coronary artery disease?
Genetic variants in CYP3A4*22, PPAR-α, and ARNT do not significantly influence clopidogrel-induced platelet inhibition in patients with coronary artery disease.
Kreutz et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: